Shares of Ocular Therapeutix, Inc. (OCUL) fell sharply on Tuesday morning even after the company reported positive Phase 3 trial results for its investigational wet age-related macular degeneration (AMD) therapy.
The stock is currently trading at $6.86, down $2.03 or 22.80%, on the Nasdaq. The stock opened at $6.41 after closing Monday at $8.88. The stock has traded between $5.78 and $16.44 in the past 52-week period.
Ocular Therapeutix reported that its Phase 3 SOL-1 superiority trial met its primary endpoint with high statistical significance, showing that AXPAXLI outperformed aflibercept in patients with wet AMD. The therapy also demonstrated strong durability and reduced treatment burden.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.